Reuters logo
BRIEF-Novogen terminates ATM-3507 preclinical development program
April 5, 2017 / 10:54 PM / 6 months ago

BRIEF-Novogen terminates ATM-3507 preclinical development program

April 6 (Reuters) - Novogen Ltd :

* Novogen terminates ATM-3507 preclinical development program

* Decision to terminate development of atm-3507 does not affect ‘next-generation atm’ program

* Novogen anticipates significant future cost savings associated with termination

* A reduction in headcount will be implemented, and other employees will be reallocated to new responsibilities

* Atm-3507 (anisina) will not be progressed into clinical trials due to “unfavourable balance of preclinical activity relative to emerging toxicology findings”

* Recently-announced crc-p grant for next-generation atm program is unaffected by the decision Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below